GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » ROIC %

Genor Biopharma Holdings (HKSE:06998) ROIC % : -238.68% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Genor Biopharma Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -238.68%.

As of today (2024-06-04), Genor Biopharma Holdings's WACC % is 11.82%. Genor Biopharma Holdings's ROIC % is -184.44% (calculated using TTM income statement data). Genor Biopharma Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Genor Biopharma Holdings ROIC % Historical Data

The historical data trend for Genor Biopharma Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings ROIC % Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial -78.90 -187.87 -165.31 -142.63 -195.78

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only -171.76 -156.13 -141.16 -134.91 -238.68

Competitive Comparison of Genor Biopharma Holdings's ROIC %

For the Biotechnology subindustry, Genor Biopharma Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's ROIC % falls into.



Genor Biopharma Holdings ROIC % Calculation

Genor Biopharma Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-754.177 * ( 1 - 0.34% )/( (505.911 + 261.884)/ 2 )
=-751.6127982/383.8975
=-195.78 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2361.953 - 225.909 - ( 1774.13 - max(0, 290.787 - 1920.92+1774.13))
=505.911

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1582.564 - 214.216 - ( 1274.779 - max(0, 251.05 - 1357.514+1274.779))
=261.884

Genor Biopharma Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-857.732 * ( 1 - 0.29% )/( (454.762 + 261.884)/ 2 )
=-855.2445772/358.323
=-238.68 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2006.539 - 189.507 - ( 1489.697 - max(0, 240.406 - 1602.676+1489.697))
=454.762

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1582.564 - 214.216 - ( 1274.779 - max(0, 251.05 - 1357.514+1274.779))
=261.884

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genor Biopharma Holdings  (HKSE:06998) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Genor Biopharma Holdings's WACC % is 11.82%. Genor Biopharma Holdings's ROIC % is -184.44% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Genor Biopharma Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings (HKSE:06998) Business Description

Traded in Other Exchanges
Address
1690 Zhangheng Road, Building 3, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL mAb drug candidate.
Executives
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hhjh Holdings Limited 2101 Beneficial owner
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager
Hh Bio Investment Fund L.p. 2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited 2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si 2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings (HKSE:06998) Headlines

No Headlines